Leading Interventional Cardiologist Dr. Giora Weisz Joins Microbot Medical’s Scientific Advisory Board
June 07 2021 - 7:00AM
Microbot Medical Inc. (Nasdaq: MBOT) continues its ongoing
commitment to strengthen and broaden its capabilities as Giora
Weisz, MD joined the Company’s Scientific Advisory Board (SAB). Dr.
Weisz is a practicing interventional cardiologist and clinical
researcher who has pioneered novel robotic-enhanced coronary
interventions, as well as navigation and positioning technologies.
His areas of expertise include cardiac catheterization, coronary
artery disease and diagnostic angiography, which make his
assistance an invaluable asset to Microbot as it continues to
develop the LIBERTY™ Robotic System.
Dr. Weisz performed the Corindus Vascular
Robotics’ (acquired by Siemens Healthineers) First-in-Human (FIH)
clinical trial to evaluate the safety and technical efficacy of
Corindus’ CorePath system in delivering and manipulating coronary
guidewires and stent/balloon systems in PCI procedures. He was also
the principal investigator of the multi-center pivotal study
leading to the FDA approval of the system. He was the first to use
this system on patients in the U.S. Dr. Weisz is often invited to
speak about robotic-enhanced interventions in national and
international medical conferences.
Dr. Weisz is an Associate Professor of Medicine
at Columbia University Medical Center, Director of Interventional
Cardiology at the New York-Presbyterian Hudson Valley Hospital, and
a member of the faculty of the Center of Interventional Vascular
Therapy at Columbia University Medical Center. He is also a faculty
member at the Cardiovascular Research Foundation in New York. Dr.
Weisz graduated from the Hebrew University-Hadassah Medical School
in Jerusalem, Israel and completed his residency in internal
medicine and cardiology fellowship at the Carmel Medical Center in
Haifa, Israel. His training in interventional cardiology was
completed at Lenox Hill Hospital in New York. As a practicing
interventional cardiologist, Dr. Weisz has particular interest in
current and innovative technologies in cardiovascular medicine.
“It is exciting to continue attracting leading
experts in their fields, including Dr. Weisz, who have experience
in the endovascular robotic space and see the value that our
LIBERTY system can add to their practice,” commented Harel Gadot,
CEO, President and Chairman. “With his extensive experience, Dr.
Weisz will be a welcome addition to our already impressive SAB.
Specifically, he will be intimately involved in the advancement of
our LIBERTY Robotic System as we aim to further enhance its
capabilities to address the sizeable cardiac market.”
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a
pre-clinical medical device company that specializes in
transformational micro-robotic technologies, focused primarily on
both natural and artificial lumens within the human body.
Microbot’s current proprietary technological platforms provide the
foundation for the development of a Multi Generation Pipeline
Portfolio (MGPP).
Microbot Medical was founded in 2010 by Harel
Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of
improving clinical outcomes for patients and increasing
accessibility through the use of micro-robotic technologies.
Further information about Microbot Medical is available at
http://www.microbotmedical.com.
Safe Harbor
Statements pertaining to the registered direct
offering, timing, the amount and anticipated use of proceeds and
statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development, and
potential opportunities for Microbot Medical Inc. and its
subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management, constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and
the Federal securities laws. Any statements that are not historical
fact (including, but not limited to statements that contain words
such as “will,” “believes,” “plans,” “anticipates,” “expects” and
“estimates”) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, market conditions and
the satisfaction of customary closing conditions, risks inherent in
the development and/or commercialization of potential products,
including LIBERTY, the outcome of its studies to evaluate the SCS
and other existing and future technologies, uncertainty in the
results of pre-clinical and clinical trials or regulatory pathways
and regulatory approvals, uncertainty resulting from the COVID-19
pandemic, need and ability to obtain future capital, and
maintenance of intellectual property rights. Additional information
on risks facing Microbot Medical can be found under the heading
“Risk Factors” in Microbot Medical’s periodic reports filed with
the Securities and Exchange Commission (SEC) and in the prospectus
supplement related to the registered direct offering to be filed
with the SEC, which are or will be available on the SEC’s web site
at www.sec.gov. Microbot Medical disclaims any intent or obligation
to update these forward-looking statements, except as required by
law.
Investor Contact:
Michael PolyviouEVC
Groupmpolyviou@evcgroup.com732-933-2754
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Sep 2023 to Sep 2024